ZoomMed Inc. has sold certain assets to TELUS Health
TELUS Health, Canada’s largest Electronic Medical Records (EMR) provider and a leader in the Canadian claims and benefits management sector, is adding important new functionality to its existing health technology portfolio through its acquisition of an interest in the underlying technology of the ZRx Prescriber from Quebec-based ZoomMed Inc. Financial details have not been disclosed.
ZoomMed Inc. is a publicly traded company (TSXV: ZMD) that builds and operates a clinical information exchange platform between physicians, pharmacists and the various other stakeholders of the Health sector with whom they interact. The company has the largest private network of electronic prescriptions and drug information system in Canada.
TELUS Health is a leader in telehomecare, electronic medical and health records, consumer health, benefits management and pharmacy management. TELUS Health solutions give health authorities, providers, physicians, patients and consumers the power to turn information into better health outcomes. It is an operating subsidiary of TELUS (TSX: T), one of Canada’s largest telecommunication companies.
“This acquisition builds upon our EMR leadership position and claims and benefits expertise, and allows us to have a more direct and positive impact on the patient experience, which ultimately leads to better health outcomes for Canadians,” said Paul Lepage, President of TELUS Health.
Oaklins' team in Montreal advised the seller in this transaction.
Contacter l'équipe de la transaction
Transactions connexes
MEDIK Hospital Design Group has been acquired by STERIS
The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.
En apprendre plusbioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.
En apprendre plusBanook, backed by Motion Equity, has acquired Fluidda
Banook Group has acquired Fluidda NV, marking a strategic expansion into advanced in-silico trials and respiratory disease modeling. Combining Banook’s expertise in cardiac safety and clinical data services with Fluidda’s AI-driven respiratory analytics creates a powerful, integrated platform. This deal strengthens Banook’s position in the contract research organization (CRO) sector, offering pharmaceutical clients broader, technology-enabled solutions to drive drug development and reduce costs.
En apprendre plus